Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 + T cell epitopes

Clinical and Experimental Immunology

Volumn 140, Issue 1, 2005, Pages 109-116

  Hammond, A S ^a   Klein, M R ^a,b   Corrah, T ^a,c   Fox, A ^a   Jaye, A ^a   McAdam, K P ^a,d   Brookes, R H ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

CTL; ELISPOT; Genome wide; Tuberculosis; Vaccine

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA B7 ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EX VIVO STUDY; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; GENOME, BACTERIAL; HLA-B ANTIGENS; HLA-B35 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; INTERFERON TYPE II; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE FRAGMENTS; TUBERCULOSIS;

EID: 16244377732     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02751.x     Document Type: Article

References (39)

1. WHO Factsheet no. 104, revised August 2002. http://www.who.int/ mediacentre/factsheets/fs104/en
2. Daniel TM. The immunology of tuberculosis. Clin Chest Med 1980; 1:189-201.
3. Agger EM, Andersen P. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine 2002; 21:7-14.
4. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001; 1:20-30.
5. Bleed DWC, Dye C, Raviglione M, eds. Global tuberculosis control: WHO report 2003. WHO/CDS/TB/2003316 (accessed 16 February 2004). Geneva: World Health Organization, 2003. http:// www.who.int/whr/2003/en
6. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
7. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 2004; 84:93-101.
8. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30:3689-98.
9. + T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages. Eur J Immunol 2003; 33:3293-302.
10. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54.
11. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002; 32:97-105.
12. Klein MR, Hammond AS, Smith SM, Jaye A, Lukey PT, McAdam KP. HLA-B*35-restricted CD8(+)-T-cell epitope in Mycobacterium tuberculosis Rv2903c. Infect Immun 2002; 70:981-4.
13. Stenger S, Niazi KR, Modlin RL. Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J Immunol 1998; 161:3582-8.
14. Stenger S, Hanson DA, Teitelbaum R et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121-5.
15. Klein MR, Fox A. Mycobacterium-specific human CD8 T cell responses. Arch Immunol Ther Exp (Warsz) 2001; 49:379-89.
16. Klein MR, Smith SM, Hammond AS et al. HLA-B*35-restricted CD8 T cell epitopes in the antigen 85 complex of Mycobacterium tuberculosis. J Infect Dis 2001; 183:928-34.
17. Allsopp CE, Harding RM, Taylor C et al. Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia. Am J Hum Genet 1992; 50:411-21.
18. Hill AV, Allsopp CE, Kwiatkowski D et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.
19. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201-12.
20. Sidney J, Southwood S, del Guercio MF et al. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. J Immunol 1996; 157:3480-90.
21. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537-44.
22. Cole ST, Eiglmeier K, Parkhill J et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409:1007-11.
23. Garnier T, Eiglmeier K, Camus JC et al. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003; 100:7877-82.
24. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002; 184:5479-90.
25. Sylvester-Hvid C, Nielsen M, Lamberth K et al. SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens 2004; 63:395-400.
26. Flower DR. Towards in silico prediction of immunogenic epitopes. Trends Immunol 2003; 24:667-74.
27. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163-75.
28. Bunce M, O'Neill CM, Barnardo MC et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46:355-67.
29. Schonbach C, Ibe M, Shiga H et al. Fine tuning of peptide binding to HLA-B*3501 molecules by nonanchor residues. J Immunol 1995; 154:5951-8.
30. Lalvani A, Dong T, Ogg G et al. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. J Immunol Meth 1997; 210:65-77.
31. Pathan AA, Wilkinson KA, Wilkinson RJ et al. High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis- infected subjects without disease. Eur J Immunol 2000; 30:2713-21.
32. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41:178-228.
33. Ellis JM, Hoyer RJ, Costello CN et al. HLA-B alele frequencies in Cote d'Ivoire defined by direct DNA sequencing: identification of HLA-B*1405, B*4410, and B*5302. Tissue Antigens 2001; 57:339-43.
34. Modigliani Y, Bandeira A, Coutinho A. A model for developmentally acquired thymus-dependent tolerance to central and peripheral antigens. Immunol Rev 1996; 149:155-20.
35. Serbina NV, Flynn JL. CD8(+) T cells participate in the memory immune response to Mycobacterium tuberculosis. Infect Immun 2001; 69:4320-8.
36. Voskuil MI. Mycobacterium tuberculosis gene expression during environmental conditions associated with latency. Tuberculosis (Edinb) 2004; 84:138-43.
37. Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177:1664-73.
38. Lalvani A, Moris P, Voss G et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 1999; 180:1656-64.
39. Bivas-Benita M, van Meijgaarden KE, Franken KL et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 2004; 22:1609-15.